Martin Lepšík

Martin Lepšík

Auto-generated profile, based on publicly available information

Martin Lepšík

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2012 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
MKMadhu Kollareddy
Madhu Kollareddy
DZDaniella Zheleva
Daniella Zheleva
PDPetr Džubák
Petr Džubák
PBPathik Subhashchandra Brahmkshatriya
Pathik Subhashchandra Brahmkshatriya
MLMartin Lepsik
Martin Lepsik
MHMarian Hajduch
Marian Hajduch
Summary: The Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation inDrosophila melanogaster.They soon became the focus of much attention because of their importance in human biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered, and are currently under development. The binding modes of Aurora kinase inhibitors to Aurora kinases share specific hydrogen bonds between the inhibitor core and the back bone of the kinase hinge region, while others parts of the molecules may point to different parts of the active site via noncovalent interactions. Currently there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and status of Aurora kinase inhibitors in preclinical, Phase I, and Phase II clinical studies, with particular emphasis on the mechanisms of action and resistance to these promising anticancer agents. We also discuss the validity of Aurora kinases as oncology targets, on/off-target toxicities, and other important aspects of overall clinical performance and future of Aurora kinase inhibitors.

3 May 2006 in Chemphyschem
Verified
Journal Article
Closed access
PDF file
JFJindrich Fanfrlik
Jindrich Fanfrlik
MLMartin Lepšík
Martin Lepšík
DHDominik Horinek
Dominik Horinek
ZHZdeněk Havlas
Zdeněk Havlas
PHPavel Hobza
Pavel Hobza

29 October 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Pavlína Maloy ŘezáčováPavlína Maloy Řezáčová
Pavlína Maloy Řezáčová
JPJana Pokorná
Jana Pokorná
JBJiří Brynda
Jiří Brynda
MKMilan Kožíšek
Milan Kožíšek
PCPetr Cígler
Petr Cígler
JKJan Konvalinka
Jan Konvalinka

27 July 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JFJindrich Fanfrlik
Jindrich Fanfrlik
APAdam Prada
Adam Prada
ZPZdeňka Padělková
Zdeňka Padělková
APAdam Pecina
Adam Pecina
JMJan Macháček
Jan Macháček
PHPavel Hobza
Pavel Hobza

14 February 2012 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
Pau Farras CostaPau Farras Costa
Pau Farras Costa
EJEmilio J. Juárez-Pérez
Emilio J. Juárez-Pérez
MLMartin Lepšík
Martin Lepšík
Rafael LuqueRafael Luque
Rafael Luque
RNRosario Nuñez
Rosario Nuñez
FTFrancesc Teixidor
Francesc Teixidor
This tutorial review will deal with the study of metallacarboranes and their interactions with other molecules from a theoretical point of view. This contribution is devoted to guide experimental chemists through calculations that some years ago were reserved to theoretical specialists. The widespread availability of fast computers enables nowadays studies of complex compounds (e.g. metallacarboranes) from different perspectives including simulation of NMR, infrared or Raman spectra and calculation of other properties such as atomic charges or inter-/intramolecular interactions. The insights gained on the basis of theoretical calculations are crucial for either finding novel or improving existing applications of metallacarboranes. For example, in the case of enzyme inhibitors, the interactions of the metallacarboranes with the surrounding protein and how the interaction affects the efficiency are difficult problems to study experimentally. The use of theoretical tools can provide a detailed understanding of the physico-chemical basis of the interactions and thus offers a chance to control the overall process.

12 September 2014 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SZSebastian Zoll
Sebastian Zoll
SSStancho Stanchev
Stancho Stanchev
JBJakub Began
Jakub Began
JŠJan Škerle
Jan Škerle
MLMartin Lepšík
Martin Lepšík
KSKvido Strisovsky
Kvido Strisovsky
The mechanisms of intramembrane proteases are incompletely understood due to the lack of structural data on substrate complexes. To gain insight into substrate binding by rhomboid proteases, we have synthesised a series of novel peptidyl‐chloromethylketone (CMK) inhibitors and analysed their interactions with Escherichia coli rhomboid GlpG enzymologically and structurally. We show that peptidyl‐CMKs derived from the natural rhomboid substrate TatA from bacterium Providencia stuartii bind GlpG in a substrate‐like manner, and their co‐crystal structures with GlpG reveal the S1 to S4 subsites of the protease. The S1 subsite is prominent and merges into the ‘water retention site’, suggesting intimate interplay between substrate binding, specificity and catalysis. Unexpectedly, the S4 subsite is plastically formed by residues of the L1 loop, an important but hitherto enigmatic feature of the rhomboid fold. We propose that the homologous region of members of the wider rhomboid‐like protein superfamily may have similar substrate or client‐protein binding function. Finally, using molecular dynamics, we generate a model of the Michaelis complex of the substrate bound in the active site of GlpG. ![][1] Despite valuable insights from inhibitor‐bound rhomboid proteases, full understanding of intramembrane proteolysis requires structural views of protease‐substrate complexes. Direct insights into substrate binding and catalytic mechanism of an intramembrane protease now come from X‐ray structures of the bacterial rhomboid protease GlpG complexed to substrate‐derived peptide inhibitors. The EMBO Journal (2014) 33: 2408–2421 [1]: pending:yes